Jane Street Group, LLC Lineage Cell Therapeutics, Inc. Transaction History

Jane Street Group, LLC

$616 Billion
Q3 2025

A detailed history of Jane Street Group, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 144,863 shares of LCTX stock, worth $275,239. This represents 0.0% of its overall portfolio holdings.

Number of Shares

144,863

Previous 1,506,396 90.38%

Holding current value

$275,239

Previous $1.37 Million 81.75%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$0.87 - $1.79 $1.18 Million - $2.44 Million	-1,361,533 Reduced 90.38%	144,863 $250,000
Q2 2025 Aug 14, 2025	BUY	$0.39 - $1.13 $560,947 - $1.63 Million	1,438,328 Added 2113.08%	1,506,396 $1.37 Million
Q1 2025 May 14, 2025	SELL	$0.45 - $0.72 $87,659 - $140,254	-194,798 Reduced 74.11%	68,068 $30,000
Q4 2024 Feb 14, 2025	BUY	$0.5 - $0.95 $71,482 - $135,816	142,965 Added 119.24%	262,866 $131,000
Q3 2024 Nov 14, 2024	SELL	$0.8 - $1.12 $98,443 - $137,820	-123,054 Reduced 50.65%	119,901 $109,000

Q2 2024 Aug 14, 2024	BUY	$0.89 - $1.47 $122,957 - $203,087	138,155 Added 131.83%	242,955 $242,000
Q1 2024 May 15, 2024	SELL	$0.86 - $1.48 $50,921 - $87,632	-59,211 Reduced 36.1%	104,800 $155,000
Q4 2023 Feb 14, 2024	BUY	$0.91 - $1.35 $110,981 - $164,643	121,958 Added 290.01%	164,011 $178,000
Q3 2023 Nov 14, 2023	BUY	$1.16 - $1.53 $21,614 - $28,508	18,633 Added 79.56%	42,053 $49,000
Q2 2023 Aug 14, 2023	SELL	$1.26 - $1.53 $722,010 - $876,726	-573,024 Reduced 96.07%	23,420 $33,000
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $546,238 - $696,454	455,199 Added 322.28%	596,444 $894,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.5 $109,367 - $160,834	107,223 Added 315.16%	141,245 $165,000
Q3 2022 Nov 14, 2022	SELL	$1.13 - $1.77 $28,199 - $44,170	-24,955 Reduced 42.31%	34,022 $38,000
Q2 2022 Aug 16, 2022	SELL	$1.12 - $1.61 $73,060 - $105,025	-65,233 Reduced 52.52%	58,977 $93,000
Q1 2022 May 17, 2022	SELL	$1.21 - $2.48 $171,657 - $351,827	-141,866 Reduced 53.32%	124,210 $191,000
Q4 2021 Feb 15, 2022	BUY	$1.84 - $2.68 $374,489 - $545,452	203,527 Added 325.39%	266,076 $652,000
Q3 2021 Nov 16, 2021	SELL	$2.26 - $2.86 $374,068 - $473,378	-165,517 Reduced 72.57%	62,549 $158,000
Q2 2021 Aug 16, 2021	BUY	$2.17 - $3.0 $341,829 - $472,575	157,525 Added 223.31%	228,066 $650,000
Q1 2021 May 18, 2021	BUY	$1.77 - $3.1 $70,492 - $123,460	39,826 Added 129.66%	70,541 $166,000
Q4 2020 Feb 17, 2021	SELL	$0.95 - $1.83 $145,373 - $280,035	-153,025 Reduced 83.28%	30,715 $54,000
Q3 2020 Nov 17, 2020	SELL	$0.75 - $1.09 $609,386 - $885,641	-812,515 Reduced 81.56%	183,740 $172,000
Q2 2020 Aug 17, 2020	BUY	$0.71 - $1.18 $572,475 - $951,438	806,304 Added 424.48%	996,255 $867,000
Q1 2020 May 15, 2020	BUY	$0.6 - $1.58 $84,889 - $223,543	141,483 Added 291.91%	189,951 $157,000
Q4 2019 Feb 14, 2020	BUY	$0.54 - $1.01 $12,042 - $22,523	22,300 Added 85.22%	48,468 $43,000
Q3 2019 Nov 14, 2019	BUY	$0.85 - $1.24 $22,242 - $32,448	26,168 New	26,168 $26,000

Others Institutions Holding LCTX

# of Institutions

128

Shares Held

96M

Call Options Held

251K

Put Options Held

50K

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $323M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Lineage Cell Therapeutics, Inc. Transaction History